Global & Europe Plant Genomics Market | Latest Statistics, Business Trends, Growth and Opportunities

Market Summary and Growth Forecast

The global & Europe Plant Genomics Market is estimated at $4,850 million in 2026 and is expected to reach $11,420 million by 2035, growing at a CAGR of 10.0%.

Plant genomics covers the commercial ecosystem around plant DNA analysis, genome sequencing, genotyping, marker-assisted breeding, genomic selection, gene-editing support, bioinformatics, and related contract research services. It does not include seed sales, crop protection revenue, or finished agricultural input sales. The revenue boundary is focused on tools, services, platforms, assays, data analytics, and applied R&D used to understand and improve plant traits.

The business relevance is becoming sharper in 2026–2035. Food systems are under pressure from climate volatility, pest resistance, water stress, changing fertilizer economics, and the need for higher yields from limited land. So, plant genomics is no longer just a lab activity. It is becoming a decision layer for seed companies, crop research institutes, ag-biotech firms, and food value chains that want faster breeding cycles and more predictable trait development.

Get a Free Sample Copy at https://datavagyanik.com/reports/plant-genomics-market-research-report-analysis-and-forecast/

Europe has a stronger role than earlier cycles. The EU’s new framework for plants obtained through targeted mutagenesis and cisgenesis was adopted in June 2026, with application expected after a transition period. This gives European crop researchers and breeding companies a clearer pathway for selected new genomic techniques, although food/feed products remain under the existing GMO framework until the new rules apply. This regulatory shift matters for the Global & Europe Plant Genomics Market because Europe has historically had strong science but slower commercialization in gene-edited crops.

Our modeled base view places Europe at $1,170 million in 2026, or about 24.1% of global demand. Europe is projected to reach $2,930 million by 2035, growing at 10.7% CAGR. This is slightly ahead of the global average, supported by public research funding, crop resilience programs, premium seed breeding, and faster adoption of genomic selection across cereals, oilseeds, vegetables, and specialty crops.

The growth case is not built on one technology. It is a stack. High-throughput sequencing reduces the cost of genome mapping. Genotyping platforms help breeders screen large populations. Bioinformatics turns raw sequence data into usable trait signals. Gene-editing tools add precision. AI and predictive models then connect genotype, phenotype, and environment. That combination shortens the distance between discovery and breeding decisions.

Key consumers and clients include seed companies, crop protection and ag-biotech firms, public agricultural research institutes, universities, contract research organizations, genomics service providers, government breeding programs, plant tissue culture labs, and food ingredient companies working on crop quality traits. Large crop producers and farmer cooperatives are not always direct buyers. But they influence demand because seed suppliers need trait packages that perform under real field stress.

Get a Free Sample Copy at https://datavagyanik.com/reports/plant-genomics-market-research-report-analysis-and-forecast/

Technology will remain the central macro force. The market is moving from single-gene research toward multi-trait modeling. Breeders want drought tolerance, nitrogen-use efficiency, pest resistance, yield stability, processing quality, and shelf-life traits together. That makes genomics spending more recurring. A one-off genome project is useful. A continuous breeding data pipeline is more valuable.

Regulation is the second macro force. Europe’s position on new genomic techniques gives the region a clearer innovation route. The European Parliament has also framed the rules around climate-resistant, pest-resistant, higher-yielding varieties and reduced fertilizer or pesticide dependence. That fits the investment thesis for the Global & Europe Plant Genomics Market: the science is being pulled by policy goals, not only by private R&D.

Production economics also matter. Seed development costs are high, and crop failure risks are rising. Genomics helps companies reduce late-stage failure by screening traits earlier. This may lead to more spending on predictive breeding platforms and contract genomics services, especially among mid-sized seed companies that cannot build full-stack in-house capabilities.

Expert view: The next phase of plant genomics will be less about who can sequence faster and more about who can convert genomic signals into field-ready breeding decisions. That is where margin and differentiation will sit.

Market Segmentation and Forecast Scope

The Global & Europe Plant Genomics Market is segmented by technology, service/product type, application, crop type, end user, and region. The segmentation logic follows how budgets are actually allocated. Buyers do not purchase “plant genomics” in a generic way. They buy sequencing runs, genotyping panels, trait discovery programs, bioinformatics workflows, CRISPR validation support, or breeding analytics.

By Technology

Genotyping and marker analysis leads in 2026 because it is already embedded in breeding workflows. It is less expensive than full genome sequencing and easier to scale across thousands of plant lines. This makes it the practical workhorse of commercial breeding.

The fastest-growing technology segment is expected to be bioinformatics and predictive analytics. The reason is simple. Sequencing data alone has limited value. Companies need models that connect DNA variation to field traits. That is where genomic selection, AI-assisted phenotype prediction, and multi-omics integration become useful.

By Service and Product Type

The market includes consumables and assay kits, sequencing services, genotyping services, bioinformatics software, data analytics platforms, contract research services, and gene-editing workflow support.

Service-based revenue is important because many breeding groups prefer outsourcing. Building internal sequencing and analytics infrastructure is expensive. It also requires specialized staff. This benefits companies such as Eurofins Genomics, Novogene, BGI Genomics, Illumina-connected service networks, and specialized agri-genomics CROs.

In Europe, outsourcing intensity is higher among public institutes and mid-sized seed firms. These buyers often use genomics vendors for low-pass sequencing, SNP discovery, marker development, and trait validation. Eurofins Genomics has positioned itself around DNA sequencing, genotyping, DNA synthesis, and bioinformatics services.

By Application

Marker-assisted breeding holds a strong share in 2026 because it is proven, scalable, and directly tied to seed pipeline productivity. That said, genomic selection is the strategic segment to watch. It predicts breeding value using genome-wide markers before full field performance is known. This reduces time and improves selection efficiency.

A 2025 review in plant science highlighted the growing evidence that genomic selection improves genetic gains in plant breeding. For the & Europe Plant Genomics Market, this is important because European breeding is strong in cereals, vegetables, sugar beet, oilseeds, and specialty crops where multi-location performance data is critical.

By Crop Type

The market is segmented into cereals and grains, oilseeds and pulses, fruits and vegetables, industrial crops, horticulture and ornamentals, and specialty crops.

Cereals and grains remain the anchor category because wheat, maize, rice, barley, and related crops have large acreage and high food-security relevance. Europe is especially strong in wheat, barley, oilseed rape, sugar beet, and vegetable seed breeding. Fruits and vegetables offer higher margin potential because quality traits, disease resistance, shelf life, and nutrition traits can carry premium value.

By End User

Key end users include seed companies, ag-biotech companies, universities, public research institutes, government crop improvement programs, contract research organizations, and food ingredient companies.

Seed companies are the most commercially important end-user group. They need genomics to reduce breeding cycles and protect market share. Public research institutes remain important because they create foundational datasets and support crop resilience work. In Europe, institutes and universities also play a larger role in early-stage gene discovery and pre-breeding.

By Region

The forecast scope covers North America, Europe, Asia Pacific, and LAMEA.

North America remains a major revenue contributor due to private seed R&D, established biotech capability, and faster commercialization pathways. Europe is moving into a more active phase after regulatory clarity around selected new genomic techniques. Asia Pacific is the fastest-volume opportunity because China, India, Japan, South Korea, and Southeast Asia are increasing crop productivity programs. LAMEA is smaller but relevant for drought tolerance, heat stress, and staple crop resilience.

Expert view: The strongest value pool will not sit in basic sequencing alone. It will sit in platforms that combine genotyping, phenotype records, field data, and trait prediction into a repeatable breeding workflow.

Market Trends and Innovation Landscape

Innovation in the Global & Europe Plant Genomics Market is shifting from research discovery to applied breeding. The old model was linear: sequence the plant, identify markers, validate traits, and then breed. The new model is more iterative. Genomic data, phenotypic data, climate data, and field trial data are being looped together to support faster selection.

R&D Evolution: From Single Traits to Breeding Systems

Plant genomics R&D is moving beyond single-trait discovery. Yield is not one gene. Drought tolerance is not one gene. Disease resistance can break when pathogen pressure changes. So, companies are investing in multi-trait and multi-environment models.

This is where genomic selection is gaining traction. It helps breeders estimate the performance of a plant line earlier in the breeding cycle. It does not replace field trials. But it can reduce the number of weak candidates that reach expensive field evaluation. USDA’s Agricultural Genome to Phenome Initiative also reflects this shift by focusing on agriculturally important crops and animals in production environments, functional genes, and genotype-to-phenotype gaps.

In Europe, R&D will likely focus on climate resilience, fertilizer-use efficiency, disease resistance, and crop quality. Wheat, barley, rapeseed, potato, tomato, and specialty vegetable crops should see higher genomics intensity.

Technology Evolution: High-Throughput, Low-Pass, and Predictive

Sequencing costs are no longer the main bottleneck. The bigger issue is interpretation. Breeding programs generate huge data volumes, but many still struggle to connect genomic variation with actual field performance.

Low-pass whole-genome sequencing is becoming attractive because it offers broader genomic coverage at lower cost. In April 2024, Eurofins Genomics AgriGenomics Europe and Gencove announced a collaboration to combine low-pass whole-genome sequencing with analytics and data management. This type of partnership signals where the market is heading: lab service plus software workflow, not just sample processing.

High-throughput sequencing capacity is also scaling. In March 2024, MGI Tech announced a collaboration with Eurofins Genomics Europe Genotyping A/S involving a high-throughput sequencer, data center appliance, and lab automation systems. For Europe, this strengthens the infrastructure side of plant and broader genomics workloads.

AI Integration: Useful, but Only Where Data Quality Supports It

AI is relevant in plant genomics, but it should not be treated as a magic layer. Its value depends on the quality of genotype data, phenotype data, environmental records, and field trial design. Poor field data will still produce poor predictions.

That said, AI is being implemented in credible ways. In 2024, an international team led by IPK Leibniz Institute, with participation from Forschungszentrum Jülich, developed deep learning models linking plant gene sequence data with mRNA copy number across several plant species. The work aimed to predict regulatory effects of gene sequence variation. This matters because regulatory regions, not just coding genes, can shape complex traits.

AI-supported genomic prediction is also becoming more practical for breeding. Recent academic work has focused on integrating machine learning and deep learning with genomic, phenotypic, and environmental datasets to improve crop improvement decisions.

Expert view: AI will not replace breeders. It will make the best breeders faster. The winning model is human judgment plus data-rich prediction.

Gene Editing and New Genomic Techniques

Gene editing is increasing the commercial relevance of plant genomics. Companies need genomics to identify targets, design edits, validate outcomes, and manage off-target or performance risk. This supports demand for sequencing, genotyping, bioinformatics, and contract validation.

In September 2024, Corteva and Pairwise announced a strategic collaboration to accelerate gene editing and climate-resilience solutions in agriculture. Corteva also said it would invest $25 million for an equity stake in Pairwise. Bayer has also described genome editing R&D focus areas around plant architecture, yield, quality, and disease resistance.

This reinforces a core market signal. Large agricultural companies are not treating genomics as a support tool only. They are embedding it into innovation strategy.

Partnerships and Platform Consolidation

The market is seeing more partnerships between sequencing providers, analytics companies, seed firms, and gene-editing specialists. This is not accidental. No single company owns the full stack equally well. A seed company may own elite germplasm. A genomics service provider may own throughput. A software company may own imputation, analytics, or data management. A gene-editing company may own design capability.

So, partnerships are becoming the practical route to scale. For the Global & Europe Plant Genomics Market, this may lead to bundled offerings: sample-to-result workflows, breeding analytics subscriptions, low-pass sequencing packages, and crop-specific trait discovery programs.

Innovation Priorities for 2026–2035

The strongest innovation themes are likely to be:

The innovation landscape is still uneven. North America is ahead in commercialization. China is scaling rapidly. Europe has strong science and now a clearer regulatory base. India and other Asia Pacific markets are building demand around food security and climate-resilient crops.

Expert view: The next decade will reward genomics platforms that can prove field relevance. Breeders will pay for better decisions, not bigger datasets.

Competitive Intelligence and Benchmarking

The Global & Europe Plant Genomics Market has a mixed competitive structure. It is not controlled by one type of player. Sequencing instrument companies, genotyping platform providers, crop science firms, agri-genomics service labs, and gene-editing specialists all compete around different parts of the value chain.

The market is best understood in three layers. The first layer is technology infrastructure. This includes sequencers, arrays, reagents, sample preparation, automation, and informatics. The second layer is service execution. This includes contract sequencing, genotyping, trait mapping, and bioinformatics. The third layer is applied crop innovation. This includes breeding programs, gene-editing pipelines, climate-resilient trait development, and commercial seed R&D.

Illumina sits at the infrastructure end of the market. Its role is not to sell finished crop traits. It enables the underlying science. Its sequencing and microarray technologies support trait screening, marker-assisted breeding, parentage testing, and genetic merit prediction in plant and animal genomics. This makes the company a core platform supplier for public institutes, ag-biotech firms, and commercial breeding labs.

Thermo Fisher Scientific competes strongly in plant genotyping workflows. Its agrigenomics portfolio is built around array-based genotyping and molecular biology systems used for identifying, validating, and screening complex genetic traits. This matters because genotyping remains the most recurring revenue pool in 2026. Many breeders still need scalable SNP-based workflows more than full genome sequencing for every sample.

Eurofins Genomics is a practical benchmark for the Europe Plant Genomics Market because it combines service coverage with regional lab presence. The company offers sequencing, genotyping, gene expression, DNA/RNA synthesis, gene synthesis, and bioinformatics services. Its relevance increases when European seed companies, universities, and public institutes choose outsourced testing instead of building full internal genomics capacity.

Novogene is positioned as a high-throughput sequencing service provider. Its plant and animal whole-genome sequencing portfolio supports genome assembly, annotation, and applied research programs. The company is especially relevant for academic projects, crop genome discovery, and outsourced sequencing where price, turnaround, and data quality are key purchase criteria.

BGI Genomics / BGI Group has a scale advantage in large sequencing programs. The company has been active in commercial plant and animal whole-genome sequencing and has supported research around commercially important plant species. Its position is strongest where high-volume sequencing, population-scale studies, and Asia-linked research networks matter.

Corteva Agriscience represents the applied end of the Global & Europe Plant Genomics Market. It uses plant genomics as a competitive lever in seed development, trait discovery, and gene editing. Its September 2024 collaboration with Pairwise shows how large seed companies are pairing internal breeding scale with specialist gene-editing capability.

Bayer Crop Science is another applied R&D leader. Its genome editing focus areas include plant architecture, yield, quality, and disease resistance. This gives Bayer a strong position in crops where genomic insight can support both breeding speed and product differentiation.

Expert view: The winners won’t be only the companies with the best sequencing machines. They’ll be the firms that connect genomic data to breeding economics. That means faster selection, lower trial failure, and stronger trait pipelines.

Regional Landscape and Adoption Outlook

The Global & Europe Plant Genomics Market is becoming more regional in its adoption pattern. The science is global, but commercialization depends on regulation, crop priorities, seed industry structure, public funding, and lab infrastructure.

United States

The United States remains the most commercially mature market. Demand is supported by private seed R&D, land-grant universities, USDA-linked programs, biotech start-ups, and a clearer route for gene-edited plant development compared with many other regions.

The country’s strongest adoption areas are maize, soybean, wheat, cotton, fruits, and vegetables. The buyer base is also broad. It includes large seed companies, crop science firms, public universities, USDA-linked researchers, genomics service labs, and precision breeding start-ups.

Funding support is meaningful. USDA’s Agricultural Genome to Phenome Initiative supports work that connects genetics, phenomics, engineering, genetic diversity, and production outcomes. The program also emphasizes crop and animal genetic improvement, diverse germplasm, and pathogen-related economic losses.

The United States Plant Genomics Market is estimated at $1,310 million in 2026 and is projected to reach $3,020 million by 2035, growing at 9.7% CAGR. The country will remain a technology and commercialization benchmark, although Europe and China are likely to close part of the gap.

Europe

Europe is entering a more active phase. The region already has strong universities, public crop institutes, seed breeding clusters, and genomics service infrastructure. Its earlier limitation was not scientific capability. It was regulatory hesitation around new genomic techniques.

That is changing. On 17 June 2026, the European Parliament and Council adopted new rules for plants obtained through targeted mutagenesis and cisgenesis. The rules will apply two years after entry into force, while products remain under existing GMO rules in the transition period.

This will support the & Europe Plant Genomics Market because companies can plan R&D with more confidence. The strongest adoption countries are expected to be Germany, France, Netherlands, United Kingdom, Denmark, Spain, and Italy. Germany and France lead in public research depth. The Netherlands is strong in vegetable seeds and horticulture. Denmark is important for service infrastructure and agri-genomics outsourcing. Spain and Italy are relevant for climate-stress crops, fruits, vegetables, and Mediterranean agriculture.

The Europe Plant Genomics Market is estimated at $1,170 million in 2026 and projected to reach $2,930 million by 2035, growing at 10.7% CAGR. Europe’s edge will be in regulated, traceable, science-led crop innovation rather than purely volume-led adoption.

China

China is one of the fastest-growing demand centers. The country’s push is strategic. Crop genetics, seed self-sufficiency, and food security are linked to national agricultural policy.

In February 2025, China announced guidelines to promote agricultural biotechnology between 2024 and 2028, including gene-editing tools and new crop varieties in wheat, corn, and soybean. The plan also emphasizes independent and controllable seed sources.

China also approved five gene-edited crop varieties and additional GM crop types in December 2024, including soybean, wheat, corn, and rice varieties. This signals a more active pathway for commercial crop biotechnology.

The China Plant Genomics Market is estimated at $760 million in 2026 and projected to reach $2,120 million by 2035, growing at 12.1% CAGR. The main adoption force is not only private R&D. It is state-linked crop modernization, domestic seed security, and national-scale sequencing capacity.

India

India is still an emerging but strategically important market. The need is clear: yield stability, heat tolerance, drought resilience, pest resistance, nutrition improvement, and reduced crop loss. The challenge is commercialization pace.

India has strong public agricultural research capability through ICAR, DBT-linked institutes, state agricultural universities, and crop-specific research centers. The strongest applied opportunity sits in rice, wheat, pulses, oilseeds, millets, cotton, banana, and horticulture crops.

India is investing in genome editing capacity through ICAR-linked programs focused on crop climate resilience and food security. The Indian Agricultural Research Institute describes work around fast-tracking crop varieties with improved yield, nutritional quality, and climate resilience using genome editing tools.

The India Plant Genomics Market is estimated at $310 million in 2026 and projected to reach $920 million by 2035, growing at 12.9% CAGR. Growth will be faster than the global average, but adoption will remain public-sector-heavy unless private seed companies expand genomics spending more aggressively.

Japan

Japan has a smaller but advanced plant genomics base. The country is strong in precision breeding, rice research, specialty crops, controlled agriculture, and food-quality traits. Its market is not volume-led like China or India. It is quality-led.

Japan has also moved earlier than many countries in creating a pathway for certain genome-edited food crops. The sale of genome-edited high-GABA tomato is a notable commercial example, and Japan has distinguished certain gene-edited products from conventional GMO treatment where foreign DNA is not present.

The Japan Plant Genomics Market is estimated at $260 million in 2026 and projected to reach $570 million by 2035, growing at 9.1% CAGR. Adoption will be strongest in rice, tomato, vegetables, functional food crops, and specialty breeding.

South Korea

South Korea is a smaller but technically capable market. It has strong life science infrastructure, university research, biosafety institutions, and growing policy debate around genome editing. Domestic cultivation of GM crops remains limited, but Korea is an important importer and a sophisticated research market.

A 2025 USDA GAIN report noted that South Korea’s 2024 draft bill to define certain genome-edited organisms without foreign genes as a new category distinct from LMOs was still pending. This regulatory uncertainty limits commercial acceleration, but it also creates upside if the framework becomes clearer.

The South Korea Plant Genomics Market is estimated at $115 million in 2026 and projected to reach $265 million by 2035, growing at 9.7% CAGR. Demand will come mainly from public research, seed science, functional crops, controlled-environment agriculture, and imported technology platforms.

Middle East

The Middle East is relevant, but not as a broad regional market. Adoption is concentrated in countries where food security, arid-climate agriculture, controlled farming, and sovereign research funding intersect. The most relevant markets are Saudi Arabia, United Arab Emirates, Israel, and Qatar.

Israel is the strongest science-led market due to agri-tech, seed innovation, irrigation technology, and crop stress research. Saudi Arabia and the UAE are more funding-led. Their interest sits in desert agriculture, controlled-environment farming, crop resilience, and food-security diversification.

The Middle East Plant Genomics Market is estimated at $140 million in 2026 and projected to reach $390 million by 2035, growing at 12.1% CAGR. The opportunity is selective. It is not a mass-market genomics story yet. It is a resilience and food-security story.

Expert view: Regional winners will differ. The United States will lead commercialization. Europe will lead regulated science-to-market adoption. China will scale. India will build through public crop programs. The Middle East will buy genomics where water stress makes conventional breeding too slow.

Recent Developments + Opportunities & Restraints

Recent Developments

Opportunities and Business Insights

Opportunity 1: Europe’s regulatory reset

Europe’s new NGT framework can unlock delayed investment. Seed companies that were earlier cautious may now accelerate work in wheat, barley, oilseed rape, potato, tomato, and vegetable crops. This is a direct upside for sequencing providers, genotyping labs, CRISPR validation vendors, and breeding analytics platforms.

Opportunity 2: Low-pass sequencing for mid-sized breeders

Low-pass whole-genome sequencing can reduce the cost barrier for breeders that cannot afford deep sequencing across large populations. This may widen adoption beyond the top seed companies. The commercial opportunity is in bundled offerings: sample prep, sequencing, imputation, analytics, and breeding decision dashboards.

Opportunity 3: AI-assisted genomic prediction

AI can support trait prediction, genotype-to-phenotype modeling, and breeding population prioritization. The near-term value is not full automation. It is decision support. Companies that combine high-quality field trial data with genomic data will have stronger pricing power.

Restraints

Restraint 1: Data quality remains uneven

Plant genomics depends on clean phenotype records, good field trial design, and consistent environmental data. Many breeding programs still have fragmented datasets. This slows AI adoption and weakens predictive accuracy.

Restraint 2: Regulatory uncertainty has not disappeared

Europe has moved forward, but implementation will take time. South Korea remains cautious. India has momentum but still needs clearer commercialization pathways. These gaps can delay private investment.

Restraint 3: Talent and bioinformatics bottlenecks

Sequencing capacity is easier to buy than interpretation capability. Skilled bioinformaticians, quantitative geneticists, and breeding data scientists remain limited. This creates a service opportunity but also constrains in-house adoption.

About Datavagyanik

Datavagyanik is a market research company with clients spread all over the world. We are knowledge partner for many firms and provides them the right knowledge and advisory. Analysts at Datavagyanik are connoisseur at Pharmaceutical, Healthcare, Energy, Manufacturing, Consumer Goods, Agritech, Defense, Materials & Chemicals and others. Common offerings included in our standard reports include market sizing, forecasting, supply chain analysis, supplier intelligence, import-export insights, market trend analysis and competitive intelligence.

Contact us:

Atul B (Sales Head)

Phone: +1 551 226 6002

Website: https://datavagyanik.com/

Email: sales@datavagyanik.com